Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2
- Development stage
- Preclinical
- Lead developer
- Heligenics
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intralesional, Intramuscular, Intravenous, Subcutaneous
01
Overview
Recombinant human interferon-alpha2 (IFN-α2) is a type I interferon cytokine that plays a critical role in the innate immune response against viral infections and malignancies. It binds to the heterodimeric interferon-alpha/beta receptor (IFNAR), consisting of IFNAR1 and IFNAR2 subunits, to activate the JAK-STAT signaling pathway. This signaling cascade induces the transcription of interferon-stimulated genes (ISGs) that mediate antiviral, antiproliferative, and immunomodulatory effects. Historically developed as approved therapeutics such as interferon alfa-2a and interferon alfa-2b for indications like hepatitis B, hepatitis C, hairy cell leukemia, and melanoma, recombinant human interferon-alpha2 is also being engineered by Heligenics. Utilizing its proprietary GigaAssay™ functional genomics platform, Heligenics is developing libraries of thousands of recombinant human interferon-alpha2 variants (including precision post-translationally modified and disulfide-bond-engineered variants) to optimize therapeutic efficacy and safety for diseases such as acute myeloid leukemia, squamous cell carcinoma, polycythemia vera, hepatitis D, and other viral infections.
- Brand names
- Intron ARoferon-A
- Other names
- interferon alpha-2interferon alpha2recombinant human interferon-alpha2recombinant human interferon-alpha2 variants
02
Targets
IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)
Beyond the preview
Go deeper on interferon alfa-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2.